GlassScriptPhysician profile
Cecily Cannon
NPI 1700076908
$14,112.19
in general payments reported to CMS, 2019-2025
45 companies · $2,197 in 2025
The $2,197 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,652 · 2020: $1,263 · 2021: $1,269 · 2022: $1,837 · 2023: $2,355 · 2024: $2,539 · 2025: $2,197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,897 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,896.71 |
| Education | $194.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,688.02 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $1,684.94 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $914.69 | 2019-2025 | Jardiance, Synjardy |
| Novo Nordisk INC | $849.87 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $660.30 | 2019-2025 | Shingrix, Arexvy, Penmenvy |
| Otsuka America Pharmaceutical, INC. | $634.78 | 2019-2025 | Rexulti |
| Allergan, INC. | $537.26 | 2019-2020 | |
| Pfizer INC. | $495.49 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $477.82 | 2021-2025 | |
| Lilly USA, LLC | $473.44 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Axsome Therapeutics, INC. | $456.96 | 2023-2025 | Auvelity |
| Astellas Pharma US INC | $397.27 | 2020-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $392.60 | 2019-2025 | Xifaxan, Trulance |
| Teva Pharmaceuticals USA, INC. | $355.90 | 2019-2025 | Austedo Xr, Austedo Xr |
| Corcept Therapeutics | $318.42 | 2024-2025 | Korlym |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $290.10 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $286.55 | 2019-2024 | Trintellix, Cuvitru |
| Radius Health, INC. | $223.30 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $165.91 | 2020-2025 | Dupixent |
| Daiichi Sankyo INC. | $161.62 | 2023-2024 | Injectafer |
| Corium, LLC | $160.30 | 2023-2025 | Azstarys |
| Novartis Pharmaceuticals Corporation | $134.96 | 2019-2023 | |
| Neurocrine Biosciences, INC. | $121.76 | 2020-2024 | Ingrezza |
| Exact Sciences Corporation | $116.85 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $105.55 | 2019-2025 | Evenity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $104.78 | 2022-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $104.71 | 2021-2025 | Eliquis, Camzyos |
| Sumitomo Pharma America, INC. | $83.42 | 2024-2025 | Gemtesa |
| Collegium Pharmaceutical, INC. | $77.22 | 2024-2025 | Belbuca, Jornay Pm, Xtampza |
| Shire North American Group INC | $76.26 | 2019 | |
| Lnhc, INC | $66.48 | 2025 | Zelsuvmi |
| Merck Sharp & Dohme LLC | $60.23 | 2019-2022 | |
| Genzyme Corporation | $57.06 | 2019 | |
| Endo Pharmaceuticals INC. | $56.41 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $47.25 | 2021-2022 | |
| Lundbeck LLC | $44.49 | 2022-2023 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $39.12 | 2021 | |
| Dexcom, INC. | $38.02 | 2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $35.24 | 2022 | |
| Verona Pharma, INC. | $27.89 | 2025 | Ohtuvayre |
| Gilead Sciences, INC. | $20.86 | 2025 | |
| Myovant Sciences INC. | $19.99 | 2022 | |
| Sanofi-Aventis U.S. LLC | $18.91 | 2019 | |
| Ironshore Pharmaceuticals INC. | $16.60 | 2023 | Jornay Pm |
| Eisai INC. | $12.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cecily Cannon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.